STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3894 by analyst upside · 2026-08-13
ADPT
Adaptive Biotechnologies Corporation
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
-0.7%
implied upside to consensus target
Current Price $25.25
Consensus Target $25.07
Bull Target $28.0
Bear Target $21.0
Analysts Covering 7
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
1
Sell
0
52-Week Low $11.92
52-Week High $26.16
YTD Return +58.7%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.40
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $308M
Profit Margin -20.7%
52-WEEK RANGE
52-Week Low $11.92
52-Week High $26.16
Current Price $25.25
Bear Target $21.0
Bull Target $28.0
● Now $25.25 ● Target $25.07
TRADING DATA
Avg Volume 2.9M
YTD Return +58.7%
Analyst Count 7
Consensus Buy
Upside to Target -0.7%
Last Updated 2026-08-13

ANALYST SUMMARY

Adaptive Biotechnologies Corporation (ADPT) is currently trading at $25.25 with a Wall Street consensus price target of $25.07, which is 0.7% below the current price over the next 12 months. 7 analysts currently cover ADPT, with a consensus rating of Buy - 86% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $28.0, while the most cautious has a target of $21.0.

ADPT operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 58.7% year-to-date and is currently trading near the upper end of its 52-week range of $11.92 – $26.16.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ADPT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG reit
Buy → Buy 2026-06-17 38% win rate (8 calls)
Morgan Stanley - Reiterated
Equal-Weight → Equal-Weight 2026-05-12 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-05-06 43% win rate (7 calls)
TD Cowen - Reiterated
Buy → Buy 2026-05-06 Building track record
Guggenheim reit
Buy → Buy 2026-05-06 62% win rate (8 calls)
BTIG reit
Buy → Buy 2026-05-06 38% win rate (8 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-02-06 43% win rate (7 calls)
BTIG - Reiterated
Buy → Buy 2026-02-06 38% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
62
out of 100
Coverage depth
16/30
Consensus clarity
24/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →